Insulet Corporation

NasdaqGS PODD

Insulet Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 1.81 B

Insulet Corporation Revenue is USD 1.81 B for the Trailing 12 Months (TTM) ending September 30, 2024, a 16.42% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Insulet Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 1.56 B, a 25.23% change year over year.
Insulet Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 1.24 B, a 19.87% change year over year.
Insulet Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 1.04 B, a 19.53% change year over year.
Insulet Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 867.70 M, a 25.08% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqGS: PODD

Insulet Corporation

CEO	Dr. James R. Hollingshead Ph.D.
IPO Date	May 15, 2007
Location	United States
Headquarters	100 Nagog Park
Employees	3,000
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Key trends

Past 5 years